IRWD
Ironwood PharmaceuticalsยทNASDAQ
--
--(--)
Market Open: --
--
--(--)
Pre-Market: --
IRWD Profile
Ironwood Pharmaceuticals, Inc.
A biopharmaceutical company that develops and commercializes gastrointestinal and inflammatory diseases treatments in the US
Biological Technology
01/05/1998
02/03/2010
NASDAQ Stock Exchange
253
12-31
Common stock
100 Summer Street, Suite 2300 , Boston, Massachusetts, 02110
--
Ironwood Pharmaceuticals, Inc., was incorporated in Delaware on January 5, 1998. On April 7, 2008, the Company changed its name from Microbia, Inc. to Ironwood Pharmaceuticals, Inc. Ironwood Pharmaceuticals, a S&P SmallCap 600 company, is a leading gastrointestinal (GI) healthcare company with a mission to advance the treatment of GI diseases and redefine the standard of care for GI patients. They are pioneers in the development of LINZESS (linaclotide), the market leader in branded prescriptions in the United States, for the treatment of adult irritable bowel syndrome (IBS-C) or chronic idiopathic constipation (CIC) with constipation.
